Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van de veiligheid en werkzaamheid op lange termijn van Lunsekimig (SAR443765) bij volwassen deelnemers met matig tot ernstig astma. (AIRPHRODITE)

18 september 2026 bijgewerkt door: Sanofi

Een open-label vervolgonderzoek om de veiligheid en werkzaamheid op lange termijn van subcutane lunsekimig te evalueren bij volwassen deelnemers met matig tot ernstig astma die deelnamen aan onderzoek DRI16762

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

Studie Overzicht

Toestand

Aanmelden op uitnodiging

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

900

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Buenos Aires, Argentinië, 1121
        • Investigational Site Number : 0320005
      • Buenos Aires, Argentinië, 1414
        • Investigational Site Number : 0320004
      • Buenos Aires, Argentinië, 1425
        • Investigational Site Number : 0320001
      • Buenos Aires, Argentinië, 1122
        • Investigational Site Number : 0320012
      • Buenos Aires, Argentinië, 1425
        • Investigational Site Number : 0320011
      • La Plata, Buenos Aires, Argentinië, B1904CUL
        • Investigational Site Number : 0320003
      • Mendoza, Argentinië, 5500
        • Investigational Site Number : 0320009
      • Mendoza, Argentinië, 5500
        • Investigational Site Number : 0320015
      • Santa Fe, Argentinië, 3000
        • Investigational Site Number : 0320010
    • Buenos Aires
      • Berazategui, Buenos Aires, Argentinië, 1886
        • Investigational Site Number : 0320007
      • Lobos, Buenos Aires, Argentinië, 7240
        • Investigational Site Number : 0320013
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinië, 2000
        • Investigational Site Number : 0320002
      • Rosario, Santa Fe Province, Argentinië, 2000
        • Investigational Site Number : 0320006
      • Rosario, Santa Fe Province, Argentinië, 2000
        • Investigational Site Number : 0320020
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentinië, 4000
        • Investigational Site Number : 0320008
      • Rio de Janeiro, Brazilië, 22241-180
        • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
      • São Paulo, Brazilië, 05403-000
        • Incor - Instituto do Coracao- Site Number : 0760011
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazilië, 40060-330
        • Associacao Proar- Site Number : 0760003
    • Goiás
      • Goiânia, Goiás, Brazilië, 74605-020
        • Universidade Federal de Goias- Site Number : 0760007
    • Paraná
      • Curitiba, Paraná, Brazilië, 80030-110
        • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
    • Pernambuco
      • Recife, Pernambuco, Brazilië, 50070-550
        • Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90610-000
        • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    • Santa Catarina
      • Blumenau, Santa Catarina, Brazilië, 89030-101
        • Hospital Dia do Pulmão- Site Number : 0760005
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • Investigational Site Number : 1240013
      • Hamilton, Ontario, Canada, L8N 4A6
        • Investigational Site Number : 1240003
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Investigational Site Number : 1240004
      • Trois-Rivières, Quebec, Canada, G8T 7A1
        • Investigational Site Number : 1240001
    • Biobio
      • Concepción, Biobio, Chili, 4070094
        • Investigational Site Number : 1520013
    • Maule Region
      • Talca, Maule Region, Chili, 3465584
        • Investigational Site Number : 1520001
    • Reg Metropolitana de Santiago
      • Recoleta, Reg Metropolitana de Santiago, Chili, 8420000
        • Investigational Site Number : 1520015
      • Santiago, Reg Metropolitana de Santiago, Chili, 7500587
        • Investigational Site Number : 1520006
      • Santiago, Reg Metropolitana de Santiago, Chili, 7500692
        • Investigational Site Number : 1520005
      • Santiago, Reg Metropolitana de Santiago, Chili, 7500698
        • Investigational Site Number : 1520004
      • Santiago, Reg Metropolitana de Santiago, Chili, 7750495
        • Investigational Site Number : 1520002
    • Valparaiso
      • Quillota, Valparaiso, Chili, 2260877
        • Investigational Site Number : 1520008
      • Viña del Mar, Valparaiso, Chili, 2531172
        • Investigational Site Number : 1520011
      • Viña del Mar, Valparaiso, Chili, 2540364
        • Investigational Site Number : 1520012
      • Beijing, China, 100144
        • Investigational Site Number : 1560011
      • Changchun, China, 130021
        • Investigational Site Number : 1560010
      • Changsha, China, 410015
        • Investigational Site Number : 1560017
      • Chengde, China, 067020
        • Investigational Site Number : 1560021
      • Guangzhou, China, 510150
        • Investigational Site Number : 1560009
      • Guangzhou, China, 510000
        • Investigational Site Number : 1560053
      • Guangzhou, China, 510163
        • Investigational Site Number : 1560001
      • Guiyang, China, 550002
        • Investigational Site Number : 1560037
      • Hefei, China, 230032
        • Investigational Site Number : 1560006
      • Hohhot, China, 010050
        • Investigational Site Number : 1560014
      • Lanzhou, China, 730000
        • Investigational Site Number : 1560030
      • Nanchang, China, 330006
        • Investigational Site Number : 1560007
      • Pingxiang, China, 337055
        • Investigational Site Number : 1560002
      • Shanghai, China, 200433
        • Investigational Site Number : 1560013
      • Shenyang, China, 110004
        • Investigational Site Number : 1560015
      • Taiyuan, China, 030001
        • Investigational Site Number : 1560057
      • Tianjin, China, 300211
        • Investigational Site Number : 1560055
      • Wenzhou, China, 325027
        • Investigational Site Number : 1560005
      • Wuhan, China, 430030
        • Investigational Site Number : 1560003
      • Wuhan, China, 430030
        • Investigational Site Number : 1560022
      • Xuzhou, China, 221006
        • Investigational Site Number : 1560004
      • Yangzhou, China, 225000
        • Investigational Site Number : 1560016
      • Zhanjiang, China, 524004
        • Investigational Site Number : 1560012
      • Leipzig, Duitsland, 04347
        • Investigational Site Number : 2760001
      • Mainz, Duitsland, 55128
        • Investigational Site Number : 2760005
      • Mosonmagyaróvár, Hongarije, 9200
        • Investigational Site Number : 3480004
      • Calicut, Indië, 673008
        • Investigational Site Number : 3560007
      • Hyderabad, Indië, 500084
        • Investigational Site Number : 3560009
      • Kanpur, Indië, 208001
        • Investigational Site Number : 3560008
      • Nagpur, Indië, 441203
        • Investigational Site Number : 3560001
      • Pune, Indië, 411057
        • Investigational Site Number : 3560004
      • Ashkelon, Israël, 7830604
        • Investigational Site Number : 3760006
      • Haifa, Israël, 3104802
        • Investigational Site Number : 3760001
      • Haifa, Israël, 3436212
        • Investigational Site Number : 3760008
      • Jerusalem, Israël, 9103102
        • Investigational Site Number : 3760003
      • Jerusalem, Israël, 9112001
        • Investigational Site Number : 3760002
      • Petah Tikva, Israël, 4941492
        • Investigational Site Number : 3760010
      • Rehovot, Israël, 7610001
        • Investigational Site Number : 3760004
      • Tel Aviv, Israël, 6423906
        • Investigational Site Number : 3760007
    • Roma
      • Rome, Roma, Italië, 00168
        • Investigational Site Number : 3800010
      • Fukushima, Japan, 960-1295
        • Investigational Site Number : 3920008
      • Kyoto, Japan, 610-0113
        • Investigational Site Number : 3920006
      • Kyoto, Japan, 612-8555
        • Investigational Site Number : 3920009
      • Miyazaki, Japan, 889-1692
        • Investigational Site Number : 3920012
    • Kagawa-ken
      • Sakaidechō, Kagawa-ken, Japan, 762-8550
        • Investigational Site Number : 3920002
    • Tokyo
      • Chūō, Tokyo, Japan, 104-0031
        • Investigational Site Number : 3920011
    • Yamaguchi
      • Ube, Yamaguchi, Japan, 755-8505
        • Investigational Site Number : 3920005
      • Chihuahua City, Mexico, 31000
        • Investigational Site Number : 4840002
      • Durango, Mexico, 34000
        • Investigational Site Number : 4840003
      • Veracruz, Mexico, 91900
        • Investigational Site Number : 4840008
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 66465
        • Investigational Site Number : 4840004
    • Querétaro
      • San Juan del Río, Querétaro, Mexico, 76800
        • Investigational Site Number : 4840005
    • Yucatán
      • Mérida, Yucatán, Mexico, 97070
        • Investigational Site Number : 4840007
      • Chęciny, Polen, 26-060
        • Investigational Site Number : 6160004
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-693
        • Investigational Site Number : 6160001
      • Madrid, Spanje, 28007
        • Investigational Site Number : 7240008
      • Madrid, Spanje, 28010
        • Investigational Site Number : 7240011
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spanje, 08017
        • Investigational Site Number : 7240009
      • Taipei, Taiwan, 110
        • Investigational Site Number : 1580003
      • Bursa, Turkije (Türkiye), 16059
        • Investigational Site Number : 7920006
      • Istanbul, Turkije (Türkiye), 34098
        • Investigational Site Number : 7920002
      • Istanbul, Turkije (Türkiye), 34854
        • Investigational Site Number : 7920003
      • Kayseri, Turkije (Türkiye), 38039
        • Investigational Site Number : 7920007
      • Kirikkale, Turkije (Türkiye), 71100
        • Investigational Site Number : 7920008
      • Mersin, Turkije (Türkiye), 33070
        • Investigational Site Number : 7920001
      • İzmit, Turkije (Türkiye), 41001
        • Investigational Site Number : 7920005
      • Bradford, Verenigd Koninkrijk, BD9 6DA
        • Investigational Site Number : 8260008
      • Chertsey, Verenigd Koninkrijk
        • Investigational Site Number : 8260005
      • London, Verenigd Koninkrijk, W1G 8HU
        • Investigational Site Number : 8260011
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 2QQ
        • Investigational Site Number : 8260001
    • Glasgow City
      • Glasgow, Glasgow City, Verenigd Koninkrijk, G12 0YN
        • Investigational Site Number : 8260004
    • Arizona
      • Chandler, Arizona, Verenigde Staten, 85224
        • Chandler Clinical Research Trials- Site Number : 8400075
      • Tucson, Arizona, Verenigde Staten, 85712
        • Tucson Clinical Research Institute- Site Number : 8400085
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80014
        • Allianz Research Institute - Aurora- Site Number : 8400026
      • Wheat Ridge, Colorado, Verenigde Staten, 80033
        • Western States Clinical Research- Site Number : 8400014
    • Florida
      • Boynton Beach, Florida, Verenigde Staten, 33435
        • Helix Biomedics- Site Number : 8400114
      • Cutler Bay, Florida, Verenigde Staten, 33157
        • Beautiful Minds Clinical Research Center- Site Number : 8400049
      • Hialeah, Florida, Verenigde Staten, 33010
        • Qway Research - Hialeah- Site Number : 8400015
      • Miami, Florida, Verenigde Staten, 33184
        • High Quality Research- Site Number : 8400039
      • Miami, Florida, Verenigde Staten, 33186
        • Innovations Biotech- Site Number : 8400040
      • Miami, Florida, Verenigde Staten, 33186
        • New Access Medical Center- Site Number : 8400043
      • Miami, Florida, Verenigde Staten, 33135
        • Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
      • Miami Lakes, Florida, Verenigde Staten, 33014
        • Deluxe Health Center- Site Number : 8400045
      • Pembroke Pines, Florida, Verenigde Staten, 33025
        • Tellabio International Research Services- Site Number : 8400083
      • Pembroke Pines, Florida, Verenigde Staten, 33029
        • Alfa Medical Research LLC- Site Number : 8400146
      • Pensacola, Florida, Verenigde Staten, 32503
        • Avanza Medical Research Center- Site Number : 8400135
      • Saint Cloud, Florida, Verenigde Staten, 34769
        • Ilumina Medical Research- Site Number : 8400095
      • Sarasota, Florida, Verenigde Staten, 34239
        • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
    • Georgia
      • Cordele, Georgia, Verenigde Staten, 31015
        • Private Practice - Dr. David Kavtaradze- Site Number : 8400081
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham & Women's Hospital- Site Number : 8400034
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63141
        • Midwest Clinical Research Center - St. Louis- Site Number : 8400006
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28287
        • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
    • Ohio
      • Toledo, Ohio, Verenigde Staten, 43617
        • Asthma & Allergy Center - Toledo- Site Number : 8400017
    • Oklahoma
      • Edmond, Oklahoma, Verenigde Staten, 73034
        • OK Clinical Research- Site Number : 8400021
    • Pennsylvania
      • DuBois, Pennsylvania, Verenigde Staten, 15801
        • Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15241
        • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
    • Texas
      • Austin, Texas, Verenigde Staten, 78759
        • Orion Clinical Research- Site Number : 8400001
      • Boerne, Texas, Verenigde Staten, 78006
        • South Texas Medical Research Institute - TTS Research- Site Number : 8400010
      • Dallas, Texas, Verenigde Staten, 75246
        • Baylor University Medical Center- Site Number : 8400002
      • El Paso, Texas, Verenigde Staten, 79903
        • Western Sky Medical Research- Site Number : 8400023
      • McKinney, Texas, Verenigde Staten, 75069
        • Metroplex Pulmonary and Sleep Center- Site Number : 8400022
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Zuid -Korea, 03722
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Zuid -Korea, 03080
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Zuid -Korea, 05030
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Zuid -Korea, 05505
        • Investigational Site Number : 4100006
      • Seoul, Seoul-teukbyeolsi, Zuid -Korea, 06351
        • Investigational Site Number : 4100005
      • Benoni, Zuid-Afrika, 1500
        • Investigational Site Number : 7100004
      • Benoni, Zuid-Afrika, 1500
        • Investigational Site Number : 7100005
      • Cape Town, Zuid-Afrika, 7530
        • Investigational Site Number : 7100003
      • Cape Town, Zuid-Afrika, 7700
        • Investigational Site Number : 7100002
      • Durban, Zuid-Afrika, 4001
        • Investigational Site Number : 7100001
      • Pretoria, Zuid-Afrika, 0157
        • Investigational Site Number : 7100006

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol

  • Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:

    • For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
    • For Study ACT18301: LABA with or without LTRA
  • Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures

  • Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:

For female participants:

  • incapable of becoming pregnant, or
  • not pregnant or breast feeding
  • no eggs donation or cryopreserving eggs

For male participants:

-- No sperm donation or cryopreserving sperm

- Capable of giving signed informed consent

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
  • Participant who was diagnosed with a new pulmonary disease which may impair lung function
  • Current smoker or active vaping of any products and/or marijuana smoking
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who are receiving prohibited concomitant medications
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Lunsekimig

Participants will receive subcutaneous injection of lunsekimig according to established dosing interval

  • Pharmaceutical form: Solution for injection in vial or pre-filled syringe (PFS)
  • Route of administration: Subcutaneous injection
Andere namen:
  • SAR443765

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Tijdsspanne: From study baseline to week 148

Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year.

From study baseline to week 148

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Annualized rate of asthma exacerbation events
Tijdsspanne: From study baseline to weeks 48, 96 and 144
From study baseline to weeks 48, 96 and 144
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Tijdsspanne: From parent study baseline to weeks 48, 96 and 144
From parent study baseline to weeks 48, 96 and 144
Serum lunsekimig concentrations
Tijdsspanne: From study baseline to week 144
From study baseline to week 144
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Tijdsspanne: From study baseline to week 144
From study baseline to week 144
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Tijdsspanne: From parent study baseline to weeks 48, 96 and 144

The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

From parent study baseline to weeks 48, 96 and 144
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Tijdsspanne: From parent study baseline to weeks 48, 96 and 144

Defined as ACQ-5 responder analysis

From parent study baseline to weeks 48, 96 and 144
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Tijdsspanne: From parent study baseline to weeks 48, 96 and 144

The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life.

From parent study baseline to weeks 48, 96 and 144

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 september 2024

Primaire voltooiing (Geschat)

20 januari 2031

Studie voltooiing (Geschat)

20 januari 2031

Studieregistratiedata

Eerst ingediend

20 september 2024

Eerst ingediend dat voldeed aan de QC-criteria

20 september 2024

Eerst geplaatst (Werkelijk)

24 september 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

21 september 2026

Laatste update ingediend die voldeed aan QC-criteria

18 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • LTS17231
  • 2025-522896-27 (Register-ID: CTIS)
  • U1111-1303-3645 (Register-ID: ICTRP)
  • 2025 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren